Palavra-chave: STEM CELL TRANSPLANTATION

IMATINIB ERA NON-HODGKIN S LYMPHOMA THALIDOMIDE RISK HEMATOPOIETIC MALIGNANCIES INTERLEUKIN-6-174CC LEPROSY HODGKIN´S DISEASE PERIPHERAL BLOOD AUTOLOGOUS HEMATOPOIETIC TNF DEXAMETHASONE ACUTE MYELOID LEUKAEMIA NON-MYELOABLATIVE HSCT BRAZILIAN SINGLE ENTER VACOP-B CHRONIC MYELOGENOUS LEUKEMIA IN PHASE CHRONIC LACOHG CHRONIC MYELOGENOUS LEUKEMIA RISK SCORE TNFA HLA-MATCHED LESS INTENSIVE REGIMEN FOLLOWED MULTIPLE MYELOMA PATIENTS CHRONIC GRAFT-VERSUS-HOST CARDIORESPIRATORY ALLOGENEIC HAEMATOPOIETIC PHL (+) ADVANCED MULTIPLE MYELOMA PROGRESSION-FREE SURVIVAL SERUM IMMUNOGLOBULIN LEVELS CHRONIC MEYLOID LEUKEMIA RADOMIZED STUDY FRENCH SOCIETY OF HAEMATOLOGY GVHD IMATINIB CYTOKINE AUTOLOGUS HAEMATOPOIETIC AEROBIC CAPACITY MALIGNANT LYMPHOMA IL2 HODGKIN S DISEASE HEMATOPOIETIC MALIGNANCIES HLA-IDENTICAL LATINAMERICAN COOPERATIVE ONCOHEMATOLOGY GROUP HEMATOPOIETIC STEM CELLS ALLOGENEIC LEUKEMIA IN CHRONIC BLOOD AUTOLOGOUS HEMATOPOIETIC MYELOCYTIC LEUKEMIA HODGKIN LYMPHOMA NHL CML AAWP EBMT GROUP NON-HODGKIN´S LYMPHOMA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IPI NHL GRAFT-VERSUS-DISEASE AHCST GEMOH MULTICENTER STUDY POLYMORPHISMS KIR/HLA PHYSIOTHERAPEUTIC PROTOCOL AUTOLOGOUS NON-HODGKIN LYMPHOMA MYELODYSPLASTIC SYNDROME F359V LATIN AMERICAN COOPERATIVE ONCOHEMATOLOGY GROUP BCR-ABL HIGH-DOSE SEQUENTIAL CHEMOTHERAPY INTERLEUKIN-2 EBMT GRAFT-VERSUS-HOST DISEASE SINGLE AUTOLOGOUS MUSCLE STRENGTH MULTIPLE MYELOMA CHEMOTHERAPY THALIDOMIDE+DEXAMETHASONE CHRONIC MYELOID LEUKEMIA